Repaglinide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.5 mg, 1 mg, 2 mg
Reference Brands: Prandin (USA)
Category:
Diabetes
Repaglinide is available in Tablets
and strengths such as 0.5 mg, 1 mg, 2 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Repaglinide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Repaglinide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Repaglinide is an oral antidiabetic medication used for the management of type 2 diabetes mellitus and is marketed under brand names including Prandin, Gluconorm, Surepost, and Novonorm, depending on the region. It belongs to the meglitinide class of antihyperglycemic agents and is indicated for use in combination with diet and exercise to improve blood glucose control in adults with type 2 diabetes.
Repaglinide works by stimulating insulin release from the pancreatic β-islet cells in response to meals, helping to reduce postprandial blood glucose spikes. Its rapid onset and short duration of action allow for flexible dosing before meals, making it effective in controlling blood sugar levels while minimizing the risk of prolonged hypoglycemia.
This medication is generally well tolerated, with hypoglycemia being the most common adverse effect, particularly if meals are skipped or carbohydrate intake is insufficient. Repaglinide offers a practical option for patients requiring targeted post-meal glucose control and can be used as part of a comprehensive diabetes management plan under medical supervision. Its widespread global availability under various brand names ensures accessibility for patients in multiple regions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing